

**CLEARBRIDGE HEALTH LIMITED**  
(Company Registration No.: 201001436C)  
(Incorporated in the Republic of Singapore)

---

**PROPOSED ISSUE OF CONVERTIBLE BONDS**

- **RECEIPT OF CONVERSION NOTICES IN CONNECTION WITH THE CONVERTIBLE BONDS;**
  - **ALLOTMENT, ISSUANCE AND LISTING OF CONVERSION SHARES; AND**
  - **COMPLETION OF THE PROPOSED ISSUE TO THE OUTSTANDING BONDHOLDERS**
- 

**1. INTRODUCTION**

1.1 The board of directors (the “**Board**”) of Clearbridge Health Limited (the “**Company**”) refers to:

- (a) the Company’s announcements dated 31 January 2019, 8 February 2019, 26 February 2019, 8 March 2019, 25 April 2019, 17 May 2019, 1 August 2019, 15 August 2019, 23 April 2020, 27 April 2020, 29 May 2020, 19 August 2020, 17 September 2021, 13 April 2023, 12 December 2024, 13 January 2025, and 24 January 2025, in relation to the Convertible Bonds issued by the Company pursuant to the subscription agreement dated 31 January 2019, the circular to shareholders of the Company dated 10 April 2019, the Amendment Deed dated 17 September 2021 and the Second Amendment Deed dated 13 April 2023;
- (b) the Company’s circular to shareholders dated 25 February 2025 (the “**Circular**”), and the Company’s announcements dated 24 February 2025 and 12 March 2025 in relation to the Company’s extraordinary general meeting held on 12 March 2025; and
- (c) the Company’s announcement dated 30 April 2025 in relation to the receipt of the listing and quotation notice from the SGX-ST for the dealing in, listing of and quotation for, 1,137,096,769 Conversion Shares on the Catalist Board of the SGX-ST (the “**LQN**”).

1.2 Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Circular.

**2. RECEIPT OF CONVERSION NOTICES IN CONNECTION WITH THE CONVERTIBLE BONDS**

The Company wishes to announce that it had received Conversion Notices from the Outstanding Bondholders, in which each Outstanding Bondholder has elected to convert the entirety of its respective Outstanding Bonds into Conversion Shares on the basis of the Adjusted Conversion Price of S\$0.0031 for each Conversion Share.

**3. ALLOTMENT, ISSUANCE AND LISTING OF CONVERSION SHARES; COMPLETION OF THE PROPOSED ISSUE TO THE OUTSTANDING BONDHOLDERS**

3.1 Following the receipt of the Conversion Notices and the LQN, the Company has completed the Proposed Issue to the Outstanding Bondholders on 2 May 2025 and an aggregate of

1,137,096,769 Conversion Shares at the Adjusted Conversion Price of S\$0.0031 for each Conversion Share have been allotted and issued to the Outstanding Bondholders by the Company on the same day in accordance with the Bond Terms and Conditions and the Letters of Undertaking ("**Completion**").

- 3.2 After Completion, the total number of issued Shares (excluding treasury shares and subsidiary holdings) has increased from 2,168,724,056 Shares to 3,305,820,825 Shares. The Company has no treasury shares and subsidiary holdings as at the date of this announcement.
- 3.3 The Conversion Shares were allotted and issued free from all claims, mortgages, charges, liens and other encumbrances whatsoever, and rank *pari passu* in all respects with and carry all rights similar to, the existing issued Shares, save that the Conversion Shares will not be entitled to any dividends, rights, allotments and/or other distributions, the record date of which falls on or before the date of allotment and issuance of the Conversion Shares.
- 3.4 The LQN is not to be taken as an indication of the merits of the Proposed Issue to the Outstanding Bondholders, the Conversion Shares and the Company, its subsidiaries and their securities.
- 3.5 The Conversion Shares are expected to be listed and quoted on the Catalist Board of the SGX-ST on 6 May 2025 and trading of the Conversion Shares is expected to commence with effect from 9:00 a.m. on 6 May 2025.

#### **4. CAUTIONARY STATEMENT**

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully and to exercise caution when trading in or dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors or other professional advisers immediately.

#### **By Order of the Board**

Andrew John Lord  
Lead Independent Director

2 May 2025

---

*This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Goh Mei Xian, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.*